GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT04347252

CompletedPhase 1

Glucagon Regulation of Glucose Metabolism

Incretin Action in Physiology and Diabetes

Lead sponsor

David D'Alessio, M.D.

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•HbA1c ≤5.9%•Healthy volunteers

Primary endpoints

•Insulin secretion•Hepatic glucose production

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04347252

Org study IDPro00065698_1

Secondary IDR01DK101991

Timeline

Milestones

Study start2019-09-24actual

Study first posted2020-04-15actual

Primary completion2021-04-16actual

Study completion2021-04-16actual

Last update posted2021-05-14actual

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Healthy, fasting glucose values ≤ 95 mg/dL or A1c ≤ 5.9%, and no first degree family members with T2DM.

Exclusion criteria

•Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR < 60 ml/kg/min); anemia (hematocrit < 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide).

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint/low confidence

Change in insulin secretion

Time frame:before and after glucagon administration, up to 1 hour

change from baseline, improvement

Primary/protocol endpoint

hepatic glucose production

Time frame:before and after glucagon administration, up to 1 hour

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Change in Glucagon concentrations

Time frame:before and after glucagon administration, up to 1 hour

concentration, descriptive

Secondary/protocol endpoint/low confidence

Change in Beta-hydroxybutyrate concentrations

Time frame:before and after glucagon administration, up to 1 hour

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.